Who Paid My Doc
Laura Chalmers
Pediatric Endocrinology Tulsa, OK Medical Doctor
NPI 1710046156 CMS profile 1209137
4444 E 41St St, 1St Floor, Ste B, Tulsa, OK 74135
General payments
$150
Research payments
$85,731
Ownership & investment interest
$0
Research they led as principal investigator
$70,480
Through program year 2025, Laura Chalmers of Tulsa, OK is reported in the CMS Open Payments database as having received $150 across 2 general payments and $85,731 in research payments paid to them. Separately, studies naming them as principal investigator received $70,480 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 94th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $150 | 2 | |
| 2024 | Research | $34,508 | 8 | |
| 2023 | Research | $51,224 | 11 |
Beside peers
- Laura Chalmers
- Pediatric Endocrinology median
- Middle half of Pediatric Endocrinology
- National median
In program year 2025, general payments to Laura Chalmers were reported at $150. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.
Show as a table
| Year | Laura Chalmers | Pediatric Endocrinology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $196 | $68–$845 | $163 |
| 2020 | $0 | $124 | $37–$722 | $114 |
| 2021 | $0 | $134 | $35–$691 | $132 |
| 2022 | $0 | $177 | $47–$726 | $149 |
| 2023 | $0 | $236 | $75–$887 | $160 |
| 2024 | $0 | $259 | $91–$979 | $164 |
| 2025 | $150 | $293 | $106–$1,640 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 47 drugsPart D claims
2,018
Drug cost
$805,550
Branded share of claims
69.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 178 | $183,111 | |
| Genotropin Somatropin | Brand | 50 | $85,147 | |
| Mounjaro Tirzepatide | Brand | 53 | $73,366 | |
| Trulicity Dulaglutide | Brand | 68 | $72,482 | |
| Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 | Brand | 54 | $59,527 | |
| Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 46 | $48,024 | |
| Jardiance Empagliflozin | Brand | 45 | $42,759 | |
| Humulin R U-500 Kwikpen Insulin Regular, Human | Brand | 15 | $33,891 | |
| Humalog Kwikpen U-100 Insulin Lispro | Brand | 75 | $21,836 | |
| Novolog Insulin Aspart | Brand | 62 | $18,145 |
The 10 drugs with the highest cost, of 47 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 12 billing codesPaid by Medicare
$22,590
Medicare patients
131
Services billed
512
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 72% | |
| Diabetes | 53% | |
| Arthritis | 32% | |
| Chronic kidney disease | 31% | |
| Depression | 20% | |
| Heart failure | 19% | |
| Ischemic heart disease | 19% | |
| Osteoporosis | 17% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
21 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Endocrinology in Oklahoma
Steven Chernausek
Pediatric Endocrinology · Oklahoma City, OK
Ankur Rughani
Pediatric Endocrinology · Oklahoma City, OK
Kenneth Copeland
Pediatric Endocrinology · Oklahoma City, OK
Rebecca Schaub
Pediatric Endocrinology · Oklahoma City, OK
Shelly Mercer
Pediatric Endocrinology · Tulsa, OK
David Sparling
Pediatric Endocrinology · Oklahoma City, OK
Related records
Pediatric Endocrinology in Oklahoma
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Endocrinology
Everyone recorded under this specialty, nationwide.
Doctors in Oklahoma
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.